5-methyl-oxazolo[5,4-b]pyridine-2-thiol | 1148033-47-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶唑并吡啶类
• 英文名称: 5-methyl-oxazolo[5,4-b]pyridine-2-thiol
• 英文别名: 5-methyl-1H-[1,3]oxazolo[5,4-b]pyridine-2-thione
• CAS: 1148033-47-9
• 化学式: C₇H₆N₂OS
• 分子量: 166.203
• InChiKey: DCUSVBCEXFHXCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methyl-oxazolo[5,4-b]pyridine-2-thiol 、 碘甲烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-Methyl-2-(methylthio)oxazolo[5,4-b]pyridine
  参考文献：
  名称：

  Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

  摘要：

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm9015075
• 作为产物：
  描述：

  2-羟基-3-氨基-6-甲基吡啶 、 硫光气 以 四氢呋喃 为溶剂， 生成 5-methyl-oxazolo[5,4-b]pyridine-2-thiol
  参考文献：
  名称：

  Discovery of 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models

  摘要：

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

  DOI：

  10.1021/jm9015075

文献信息

• [EN] DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR<br/>[FR] COMPOSÉS DE DIAZÉPANE QUI MODULENT LE RÉCEPTEUR CB2
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009055357A1

  公开（公告）日：2009-04-30

  Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公开了公式(I)的化合物。根据发明的化合物能够结合并成为CB2受体的激动剂、拮抗剂或反向激动剂，并且用于治疗炎症。其中作为激动剂的化合物还可额外用于治疗疼痛。
• Diazepane Compounds Which Modulate The CB2 Receptor
  申请人：Cirillo Pier Francesco

  公开号：US20100261708A1

  公开（公告）日：2010-10-14

  Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公开了化学式（I）的化合物。发明的化合物与CB2受体结合并作为激动剂、拮抗剂或反向激动剂，对治疗炎症有用。那些作为激动剂的化合物还可用于治疗疼痛。
• Discovery of 4-(5-Methyloxazolo[4,5-<i>b</i>]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a Novel α7 Nicotinic Acetylcholine Receptor Agonist for the Treatment of Cognitive Disorders in Schizophrenia: Synthesis, SAR Development, and in Vivo Efficacy in Cognition Models
  作者：Christopher J. O’Donnell、Bruce N. Rogers、Brian S. Bronk、Dianne K. Bryce、Jotham W. Coe、Karen K. Cook、Allen J. Duplantier、Edelweiss Evrard、Mihaly Hajós、William E. Hoffmann、Raymond S. Hurst、Noha Maklad、Robert J. Mather、Stafford McLean、Frank M. Nedza、Brian T. O’Neill、Langu Peng、Weimin Qian、Melinda M. Rottas、Steven B. Sands、Anne W. Schmidt、Alka V. Shrikhande、Douglas K. Spracklin、Diane F. Wong、Andy Zhang、Lei Zhang

  DOI：10.1021/jm9015075

  日期：2010.2.11

  A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective Compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.